Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099 on ClinicalTrials.gov · last registry update 2026-08-21
Recruiting now, toward 290 participants. Due to report May 2028. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 290
- Started
- 2025-06-26
- Primary completion
- 2028-05 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction
Conditions studied
Crohn's Disease · Obesity or Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.